A composition and method for treating equine sarcoids includes providing a composition ingestible by a horse wherein the composition comprises Manuka honey, chia seeds, and spirulina powder. A dosage, being an effective amount of the composition, is fed to a horse having one or more equine sarcoids.

Provided is Lactobacillus kefiri MSR101, having the accession member being CGMCC No. 17506. The strain has acid resistance, bile salt resistance, resistance to phenol, antibiotic resistance, antioxidant activity, cell surface hydrophobicity, adhesion to intestinal epithelial cells, and a cholesterol-lowering function.

Provided is Lactobacillus kefiri MSR101, having the accession member being CGMCC No. 17506. The strain has acid resistance, bile salt resistance, resistance to phenol, antibiotic resistance, antioxidant activity, cell surface hydrophobicity, adhesion to intestinal epithelial cells, and a cholesterol-lowering function.

The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

A method for modifying the genome of a lytic target phage, uses of the method and products thereof are described. Compositions comprising such phage are also described. The compositions may be formulated as a medicament, which are useful for human treatment and may treat various conditions, including bacterial infections.

A method for modifying the genome of a target phage is described. Compositions comprising such modified phage are also described. The compositions may be formulated as a medicament, which are useful for human treatment and may treat various conditions, including bacterial infections.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention provides a method for proliferating neural progenitor cells and a composition for treating neurological diseases, the composition including a proliferated neural progenitor cell. When a fetal neural progenitor cell is cultured under a hypoxia condition and/or in a medium containing tocoperol, tocoperol acetate, or a mixture thereof, the improved cell proliferation rates of the fetal neural progenitor cell are confirmed. In addition, considering an effect of the neural progenitor cell on preventing differentiation thereof into neurons at the time of proliferation, the present disclosure may contribute to mass production of neural stem cells, and accordingly, the proliferated neural progenitor cell is expected to be utilized in the treatment of a neurological disease.

A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; and recovering the cleansed product. A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; wherein at least one of the hydroxyapatite, carbonaceous material and support matrix is functionalized.

A platelet-rich plasma (PRP) activation system for activating PRP contained in a container includes a housing, a power supply, a piezoelectric transducer array, a support structure, and a coupling medium. The power supply is located in the housing. The piezoelectric transducer array is operably connected to the power supply and is located in the housing. The piezoelectric transducer array is configured to generate a focused shock wave using power from the power supply. The support structure is operably connected to the housing and is configured (i) to receive the container, and (ii) to position the container at least partially within the housing, such that at least a portion of the PRP is located at a focal volume formed by the focused shock wave. The coupling medium is located in the housing and is positioned between the piezoelectric transducer array and the container.